Media December 11, 2023: ASH 2023: microbiome-based therapy shows potential in graft-versus-host disease – EPR MaaT PharmaJanuary 22, 2024
Media December 11, 2023: MaaT Pharma : dans la maladie aigüe du greffon contre l’hôte, MaaT Pharma annonce des résultats prometteurs – BFM Bourse (French only) MaaT PharmaJanuary 22, 2024
Media December 5, 2023: En Isère, au cœur du nouveau site de MaaT Pharma pour produire son traitement microbiote – L’Usine Nouvelle (French only) MaaT PharmaJanuary 22, 2024
Media November 28, 2023: “Microbiote tous en selles !” – France Culture (French only) MaaT PharmaJanuary 22, 2024
Media October 2, 2023: Interview of Hervé Affagard – La Bourse et La Vie TV (French only) MaaT PharmaOctober 3, 2023
Media September 23, 2023: BFM Business interview of Hervé Affagard – Check-up Santé (French only) MaaT PharmaSeptember 25, 2023
Media September 19, 2023: Le Point – Traitement des cancers : le microbiote intestinal passe en phase industrielle (French only) MaaT PharmaSeptember 22, 2023
Media September 13, 2023: Endpoints News – MaaT Pharma and CDMO Skyepharma unveil bespoke, and potentially largest, microbiome facility in Europe MaaT PharmaSeptember 22, 2023
Media July 7, 2023: France 2- Les pouvoirs extraordinaires du corps humain (French only) The Extraordinary Powers of the Human Body Stomachaches, Depression, Cancer: The Microbiota RevolutionMaaT PharmaJuly 7, 2023
Media April 28, 2023: Microbiome Times – FDA Lifts Hold on Maat Pharma’s Phase 3 Investigational NDA for MaaT013 MaaT PharmaMay 3, 2023
